Maraviroc and reverse transcriptase inhibitors combinations as potential preexposure prophylaxis candidates
- 24 April 2016
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 30 (7), 1015-1025
- https://doi.org/10.1097/qad.0000000000001043
Abstract
Objective: Receptive anal intercourse in both men and women is associated with the highest probability for sexual acquisition of HIV infection. As part of a program to develop an effective prevention strategy, we performed an ex-vivo preclinical evaluation to determine the efficacy of multiple double combinations of maraviroc (MVC) and reverse transcriptase inhibitors (RTIs). Design: The entry inhibitor, MVC, a nucleotide RTI, tenofovir and two non-nucleoside RTIs, UC781 and TMC120 (dapivirine, DPV), were used in double, combinations against a panel of CCR5-using clade B and clade C HIV-1 isolates and against MVC-escape variants. A gel-formulated version of MVC-DPV combination was also tested. Methods: Indicator cells, cocultures of immature dendritic cells with CD4(+)T cells, and colorectal tissue explants were used to assess antiviral activity of drug combinations. Results: All dual MVC-RTI combinations tested inhibited MVC-sensitive and resistant isolates in cellular and colorectal explants models. All the combinations were positive with no reduction in the activity of MVC. In tissue explants, the combinations against all viral isolates tested produced an increase in the activity of MVC. An initial gel-formulation of MVC-DPV combination showed greater and prolonged antiviral activity of MVC in mucosal tissue explants. Conclusion: This study demonstrates that combinations based on antiretroviral drugs inhibiting HIV transmission at viral entry and reverse transcription have potential as prevention strategies against colorectal transmission of HIV-1 including MVC-resistant isolates. Preclinical evaluation with colorectal tissue explants indicates that a gel-formulation of MVC-DPV is an effective candidate colorectal microbicide.This publication has 49 references indexed in Scilit:
- A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutationsRetrovirology, 2013
- A Phase 1 Randomized, Double Blind, Placebo Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel (MTN-007)PLOS ONE, 2013
- Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maravirocJournal of Controlled Release, 2011
- Microbicides: Topical Prevention against HIVCold Spring Harbor Perspectives in Medicine, 2011
- Protection of Rhesus Macaques from Vaginal Infection by Vaginally Delivered Maraviroc, an Inhibitor of HIV‐1 Entry via the CCR5 Co‐ReceptorThe Journal of Infectious Diseases, 2010
- Acceptability of UC781 Gel as a Rectal Microbicide Among HIV-Uninfected Women and MenAIDS and Behavior, 2009
- Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative WomenJAIDS Journal of Acquired Immune Deficiency Syndromes, 2009
- Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infectionThe Journal of Experimental Medicine, 2009
- Reverse Transcriptase Inhibitors as Potential Colorectal MicrobicidesAntimicrobial Agents and Chemotherapy, 2009
- Maraviroc for Previously Treated Patients with R5 HIV-1 InfectionThe New England Journal of Medicine, 2008